Merck SharpDohme LLC
H1 receptor antagonist(Merck Sharp & Dohme LLC)은 Lung Neoplasm Malignant 표적 치료제로, Ovarian Cancer; Fallopian Tube Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits glioblastoma cell growth primarily through G 1 arrest and cytoskeletal remodeling, with minimal contribution from classical cell death pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 6% (ClinicalTrials.gov NCT00332163). 차별점: novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases.
Lung Neoplasm Malignant
Ovarian Cancer; Fallopian Tube Cancer
Recruiting
Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade wi
ADCs
linker that traverses the polar tunnel between S1' and S3' pockets, and its carboxylat
lentivirally transduced with PD-L1
humanized mice
novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases
inhibits glioblastoma cell growth primarily through G 1 arrest and cytoskeletal remodeling, with minimal contribution from classical cell death pathway
Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation
payload ADCs in combination with PD-L1&4-1BB bispecific antibodies
PD-1/PD-L1 resistance in oncogenic driver mutation-positive
escape capabilities, and consequential impacts on health services, requires effective antiviral therapeutics
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
H1 receptor antagonist(Merck Sharp & Dohme LLC)은 Lung Neoplasm Malignant 표적 치료제로, Ovarian Cancer; Fallopian Tube Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits glioblastoma cell growth primarily through G 1 arrest and cytoskeletal remodeling, with minimal contribution from classical cell death pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 6% (ClinicalTrials.gov NCT00332163). 차별점: novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases.
Lung Neoplasm Malignant
Ovarian Cancer; Fallopian Tube Cancer
Recruiting
Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade wi
ADCs
linker that traverses the polar tunnel between S1' and S3' pockets, and its carboxylat
lentivirally transduced with PD-L1
humanized mice
novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases
inhibits glioblastoma cell growth primarily through G 1 arrest and cytoskeletal remodeling, with minimal contribution from classical cell death pathway
Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation
payload ADCs in combination with PD-L1&4-1BB bispecific antibodies
PD-1/PD-L1 resistance in oncogenic driver mutation-positive
escape capabilities, and consequential impacts on health services, requires effective antiviral therapeutics
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.